ライフサイエンスコーパス: QTc

1 QTc interval >/=500 ms increased the risk of cardiac eve

2 QTc interval prolongation was defined as QTc interval >5

3 QTc prolongation is associated with a significantly incr

4 QTc prolongation requiring a reduction in the dose of in

5 QTc prolongation was observed in all patients (by 60 +/-

6 QTc was calculated using Framingham formula (QTc(Fram)).

7 e > 13 years, hazard ratio: 1.90; p = 0.002; QTc duration, 8% risk increase per 10-ms increment; p =

8 cope [1], symptoms on therapy [2], LQT3 [1], QTc>520 ms [6]).

9 A QTc duration > 500 ms and a history of prior syncope ide

10 atio (OR) for QTc prolongation, defined as a QTc >/= 450 msec in men and >/= 460 msec in women, was 1

11 en) and were 1.4 times more likely to have a QTc interval above 500 ms.

12 erval: 1.52 to 3.54, p < 0.001) for having a QTc interval >/=99th percentile (>/=458 ms).

13 Having a QTc interval lower than the first percentile (</=372 ms)

14 IV, hepatitis B, or hepatitis C infection; a QTc Fridericia of more than 480 ms; and substantial card

15 10-year-old female patient with LQTS with a QTc of 500 milliseconds who experienced recurrent exerti

16 However, idiopathic abnormal QTc prolongation was associated with 5-fold increased od

17 20 ms), physicians should examine the actual QTc value displayed on the report before concluding that

18 +) <3.5 mEq/L (2.1 [1.5-2.9]), and admitting QTc >450 ms (2.3; confidence interval [1.6-3.2]).

19 sociation persisted after adjusting for age, QTc, exercise-induced wall motion abnormalities, and lef

20 e of events occurring more than 2 years ago, QTc of 530 ms or longer was associated with increased ri

21 pregnant women) with cardiac parameters, all QTc intervals were within normal limits, with no signifi

22 Although QTc interval prolonged in 100% of patients, T-wave chang

23 al QRS and T vectors, J-point deviation, and QTc prolongation.

24 s from patients with autoimmune diseases and QTc prolongation were tested on IKr using HEK293 cells e

25 , PR intervals (P = 0.014), QRS duration and QTc interval (both P = 0.003), but Normal-VLDL did not.

26 Median PR interval, QRS duration, and QTc interval were 156, 88, and 402 ms, respectively.

27 ts (PR interval, QRS axis, QRS duration, and QTc interval) were evaluated for single-nucleotide polym

28 enerated by the blow, mean QRS duration, and QTc variability remained significant correlates of risk,

29 ridol group vs six in the placebo group) and QTc prolongation (seven patients in the haloperidol grou

30 s: (1) Overview of Arrhythmia, Ischemia, and QTc Monitoring; (2) Recommendations for Indication and D

31 Diabetes mellitus and QTc-affecting drugs determined QTc prolongation and were

32 ariate model, gender, diabetes mellitus, and QTc-prolonging drugs were significant determinants of QT

33 release were larger and action potential and QTc duration longer in LDLr(-/-) and ApoA1(-/-) than in

34 Tc) on drug therapy, the magnitude of QT and QTc interval prolongation, and the change in T(peak) to

35 sinus slowing and increased PR, QRS, QT, and QTc intervals, as seen with azithromycin overdose.

36 y the blow, mean QRS duration, mean QTc, and QTc variability.

37 n, estimated glomerular filtration rate, and QTc interval.

38 whereas clinical factors, including sex and QTc duration, were associated with a significant increas

39 uptake on positron emission tomography, and QTc prolongation on the ECG.

40 QTc interval prolongation was defined as QTc interval >500 ms or increase in QTc of >/=60 ms from

41 d QT (QTc) interval prolongation (defined as QTc>500 ms or an increase of >60 ms from baseline) occur

42 The animal model of autoimmune-associated QTc prolongation is the first to provide strong evidence

43 osis and management of autoimmune-associated QTc prolongation.

44 The average QTc was greater in either D-LQTS or P-LQTS than in No-LQ

45 A baseline QTc of > or =500 ms has been shown to be associated with

46 nt association remained between the baseline QTc value and the risk of subsequent cardiac events (HR

47 Propranolol has a significantly better QTc shortening effect compared to metoprolol and nadolol

48 dy, a J-shaped association was found between QTc interval duration and risk of AF.

49 ttle is known about the relationship between QTc and risk of stroke.

50 SCD among subjects with normal or borderline QTc.

51 T interval [QTc] > or = 470 ms), borderline (QTc 440 to 469 ms), and unaffected (QTc < 440 ms) subgro

52 diagnosing LQTS on the basis of "borderline" QTc values, and interpretation of a vasovagal fainting e

53 n general, vandetanib is well tolerated, but QTc prolongation remains a potential concern demanding c

54 .2% from males), a prolonged 12SL-calculated QTc value (ie, >/=470 ms in females >60 years old, and >

55 Kr , lengthen the action potential and cause QTc prolongation on the surface ECG.

56 generate pathogenic inhibitory Abs and cause QTc prolongation.

57 on in liver transaminases and dose-dependent QTc prolongation without apparent complications were obs

58 puter declared 3588 (42.1%) "Normal" despite QTc prolongation.

59 mellitus and QTc-affecting drugs determined QTc prolongation and were predictors of SCD in coronary

60 h heart rate-corrected QT interval duration (QTc) nor cardiac events in any of the 3 mutation groups.

61 , heart-rate-corrected QT interval duration (QTc), deceleration capacity, and white blood cell count

62 ine levels and a longer electrocardiographic QTc interval than did the sham group.

63 athy, including cardiac isoenzyme elevation, QTc interval prolongation, and rapidly reversible cardia

64 were more prevalent in people with epilepsy (QTc prolongation: 5% vs 0%; p=0.002; ERP: 34% vs 13%, p<

65 When added to the QTc (C statistic 0.68 for QTc alone), discrimination improved to 0.78.

66 The adjusted odds ratio (OR) for QTc prolongation, defined as a QTc >/= 450 msec in men a

67 xhibited significantly reduced potential for QTc elongation in a cardiovascular safety model.

68 iables predicts patients at highest risk for QTc interval prolongation and may be useful in guiding m

69 ed to a patient at moderate or high risk for QTc interval prolongation, a computer alert appeared on

70 DSS incorporating a validated risk score for QTc prolongation influences the prescribing of QT-prolon

71 DSS incorporating a validated risk score for QTc prolongation was developed and implemented using inf

72 es were required to have an ECG suitable for QTc analysis before and unrelated to the occurrence of S

73 QTc was calculated using Framingham formula (QTc(Fram)).

74 Female gender, QTc interval > or =500 ms, and interim syncopal events d

75 with information regarding genotype, gender, QTc duration, and history of cardiac events.

76 f 91(36.3%) patients, and 3 of 91 (3.2%) had QTc >500 ms.

77 Forty-five patients (35 men, 76%) had QTc </=340 ms, for a prevalence of 0.05%.

78 e correction formula, 102 patients (90%) had QTc greater than 470 ms, including 74 (65%) above 500 ms

79 sh/wk had a 29.2% lower likelihood of having QTc intervals >0.45 s (P=0.03).

80 binary outcome meta-analyses (human height, QTc interval and gallbladder disease); all previous repo

81 In the 50 patients analyzed with IE, QTc interval prolonged in 50 of 50 (100%) patients (from

82 olongation was defined solely as increase in QTc >/=60 ms from baseline.

83 0.82, 6.8) and a 2.5-millisecond increase in QTc (95% confidence interval: 0.11, 4.9).

84 duced ejection fraction, and (4) increase in QTc from baseline.

85 fined as QTc interval >500 ms or increase in QTc of >/=60 ms from baseline; for patients who presente

86 rmal limits, with no significant increase in QTc prolongation with increasing courses of DP.

87 of stroke was estimated per 1-SD increase in QTc(Fram), (HR [95% CI]: 1.12 [1.03 to 1.21], p = 0.0053

88 ents, there is a considerable variability in QTc measures in serial follow-up ECGs.

89 mouse models show similar problems including QTc interval prolongation and hypothermia.

90 Dofetilide monotonically increased QTc and APD throughout 6.5-hour exposure.

91 c repolarization disturbances with increased QTc intervals in both patients and controls, but with a

92 er-range QTc, in whom a patient's individual QTc may provide less incremental prognostic information.

93 < 0.0001]), whereas the patient's individual QTc was not associated with a significant risk increase

94 ibitory Abs to the HERG E-pore region induce QTc prolongation in immunized guinea-pigs by targeting t

95 ic QT score was correlated with drug-induced QTc prolongation.

96 ll patients developed corrected QT interval (QTc interval) prolongation (median QTc interval 504 ms,

97 ignificantly with the corrected QT interval (QTc) and clinical diagnostic score ranging from 0% when

98 rienced dose-limiting corrected QT interval (QTc) prolongation, pneumonitis, or neuropathic pain.

99 The corrected QT interval (QTc) should be assessed as a routine when obtaining elec

100 , prolongation of the corrected QT interval (QTc) was associated with an independent increased risk o

101 ngation of heart rate-corrected QT interval (QTc), an arrhythmia risk marker.

102 ariants on heart rate-corrected QT interval (QTc), cardiac events, and disease severity.

103 al syncope and normal corrected QT interval (QTc).

104 syncope and markedly prolonged QT interval (QTc, 530 ms).

105 graphically affected (corrected QT interval [QTc] > or = 470 ms), borderline (QTc 440 to 469 ms), and

106 ng childhood included corrected QT interval [QTc] duration > 500 ms (hazard ratio [HR]; 2.72; 95% con

107 ars, average referral corrected QT interval [QTc] of 481 ms) referred with a diagnosis of LQTS.

108 ge, QRS duration, and corrected QT interval [QTc]) were evaluated by using multivariable regression a

109 ed absolute and rate-corrected QT intervals (QTc) on drug therapy, the magnitude of QT and QTc interv

110 The median baseline corrected QT intervals (QTc) were 444 ms (gene negative), 456 ms (LQT1), 486 ms

111 1A (QRS duration), NOS1AP, KCNH2, and KCNQ1 (QTc interval).

112 g per day, 2 of 4 patients had dose-limiting QTc prolongation or pancreatitis.

113 prevalence and factors associated with long QTc interval in a cohort of opioid-dependent HIV-infecte

114 trophy (77% versus 58%; P=0.02) and a longer QTc interval (466+/-36 versus 453+/-41 milliseconds; P=0

115 Device patients had longer QTc intervals (p = 0.03) and more symptoms (p < 0.001).

116 d-type but not LOX-1(-/-) mice showed longer QTc compared to L1-injected animals in vivo with corresp

117 ne and lansoprazole had significantly longer QTc intervals (up to 12 ms in white men) and were 1.4 ti

118 The association with respect to longer QTc intervals was stronger for the outcome of lone AF, a

119 LV scar (n = 106) was associated with longer QTc (beta = 4.3 msec, P = .031).

120 nsumed >300 g fish/wk had a mean 13.6% lower QTc (P<0.01).

121 consumption of fish is associated with lower QTc interval in free-eating people without any evidence

122 Mean time to maximal QTc interval prolongation, changes in T-wave polarity, >

123 D difference between the minimum and maximum QTc values on serial ECGs recorded in study patients was

124 The maximum QTc interval provides incremental prognostic information

125 The maximum QTc interval recorded before age 10 was the strongest pr

126 After adjusting for the maximum QTc value during follow-up, no significant association r

127 Mean QTc interval was prolonged by 2.4 ms.

128 Mean QTc was significantly longer in cases than in controls (

129 ventricular repolarization delay (19.6% mean QTc prolongation in females; P<0.05) and aldosterone-dep

130 was 70 mg/day (range 15-250 mg/day) and mean QTc interval was 438 +/- 34 ms.

131 nerated by the blow, mean QRS duration, mean QTc, and QTc variability.

132 The mean QTc intervals were longer at peak exercise in patients (

133 sian, age at diagnosis 20 +/- 15 years, mean QTc 428 +/- 29 ms), with either clinical diagnosis of CP

134 mean age at diagnosis, 10.0+/-10 years; mean QTc, 528+/-74 ms) with LQTS who underwent LCSD between 2

135 nts </=21 years with electronically measured QTc of 140 to 340 ms.

136 Median QTc did not change among patients with LQTS (461+/-60 to

137 s (interquartile range, 280-360), and median QTc 323 ms (IQR, 313-332).

138 ent with mexiletine was 22 years, and median QTc interval before therapy 509 ms.

139 interval (QTc interval) prolongation (median QTc interval 504 ms, IQR: 477 to 568 ms) within 24 h of

140 We revealed Amiodarone-mediated QTc prolongation, HR reduction and HRV increase otherwis

141 symptomatic, heart rate 76 +/- 16 beats/min, QTc 472 +/- 46 ms) were started on beta-blocker therapy

142 nd APD more at 6.5 hours than at 50 minutes (QTc) or 30 minutes (APD) dofetilide administration.

143 ed that among patients with mild to moderate QTc duration (<500 ms), the risk associated with TRP was

144 for patients who presented with QTc >500 ms, QTc prolongation was defined solely as increase in QTc >

145 ion: 102+/-4 and 106+/-3 versus 84+/-3.1 ms; QTc: 50.9+/-1.3 and 52.8+/-0.8 versus 43.5+/-1.2 ms).

146 In all 74 patients analyzed with MUSE, QTc interval prolonged from 423 +/- 25 ms to 455 +/- 34

147 In nonathletes, QTc interval abnormalities comprised the majority (52%)

148 almost 3 times the risk in those with normal QTc(Fram) (hazard ratio [HR] [95% confidence interval (C

149 s stopped for 105 patients (7.5%) because of QTc prolongation or TdP.

150 cond-most common primary suspect in cases of QTc prolongation or torsade de pointes after dofetilide

151 rrhythmia or cardiac arrest and 379 cases of QTc prolongation or torsade de pointes were associated w

152 nging drugs were significant determinants of QTc prolongation in controls.

153 A continued search for novel determinants of QTc prolongation such as genomic factors is likely to en

154 ic role of anti-Ro Abs in the development of QTc prolongation.

155 interpretation of the normal distribution of QTc values, and misinterpretation of symptoms appear to

156 population controls uncovered enrichment of QTc-prolonging alleles in patients for 2 SNPs, located r

157 Whereas the incidence of QTc prolongation and extrapyramidal symptoms was similar

158 In the validation group, the incidences of QTc prolongation were 15% (low risk); 37% (moderate risk

159 SNPs previously identified as modulators of QTc-interval in genome-wide association studies in the g

160 s versus No-LQTS) included overestimation of QTc, diagnosing LQTS on the basis of "borderline" QTc va

161 Independent predictors of QTc prolongation included the following: female (odds ra

162 cal evidence demonstrates high prevalence of QTc prolongation and complex ventricular arrhythmias in

163 nce a day 21/7 had a grade 3 prolongation of QTc; and two patients on a schedule of vemurafenib 960 m

164 Monthly reports of QTc prolongation or torsade de pointes increased from a

165 QT-prolonging drugs and reduces the risk of QTc interval prolongation in hospitalized patients with

166 ependently associated with a reduced risk of QTc prolongation (adjusted odds ratio, 0.65; 95% confide

167 Despite the known risk of QTc prolongation with ziprasidone treatment, the finding

168 onfidence interval, 1.32 to 2.96) and use of QTc-prolonging drugs (odds ratio, 2.90; 95% confidence i

169 in use, aspirin use, QRS duration and use of QTc-prolonging drugs, the risk of stroke remained signif

170 However, the value of QTc measurements on follow-up ECGs in risk assessment ha

171 s of innate and drug-induced IKs blockade on QTc prolongation.

172 To examine the direct effect of L5 on QTc, mice were intravenously injected with L5 or L1.

173 y medication use for either QT (P = 0.93) or QTc (P = 0.58).

174 ite" (clinical diagnostic score >or=4 and/or QTc >or=480 ms) cases of LQTS and >1300 healthy controls

175 multivariable-adjusted model) and when other QTc correction formulas including those of Hodge, Bazett

176 ion, while those with TdP and/or a postnatal QTc more than 500 ms have SCN5A, KCNH2 or uncharacterize

177 heart rate (r=0.700; P<0.001), and postnatal QTc (r=-0.762; P<0.001) were found.

178 Fetal rhythm phenotype and postnatal QTc can predict postnatal rhythm and suggest genotype: b

179 1 to 21 points, respectively, best predicted QTc prolongation (C statistic=0.823).

180 Prolonged QTc interval (>450 ms) was documented in 33 of 91(36.3%)

181 Prolonged QTc interval was an independent predictor of posttranspl

182 A prolonged QTc interval and Q wave were related to post-transplant

183 Cirrhotics had a prolonged QTc interval, a Q wave, abnormal QRS axis deviation, ST

184 family members, none of whom had a prolonged QTc interval.

185 However, abnormally prolonged QTc in the absence of diabetes and QT-prolonging medicat

186 ndrome (SIDS), one with documented prolonged QTc and Torsade de Pointes (TdP), and in an adult woman

187 nt cardiac arrest and dramatically prolonged QTc interval who were both born to healthy parents.

188 ith likely pathogenic variants had prolonged QTc.

189 score comprising renal impairment, prolonged QTc interval, and age older than 52 was developed for pr

190 We evaluated determinants of prolonged QTc and the relationship of prolonged QTc to SCD risk am

191 wing in recent years, and cases of prolonged QTc interval and torsades de pointes have been described

192 The prevalence of prolonged QTc interval in opioid-dependent HIV-infected patients o

193 longed QTc and the relationship of prolonged QTc to SCD risk among patients with coronary artery dise

194 aive (P = .036) were predictive of prolonged QTc.

195 ly 7709 (47.5%) of these ECGs with prolonged QTc did the automated interpretation include an accompan

196 (</= 440 ms [n = 469]), LQTS with prolonged QTc interval (> 440 ms [n = 1,392]), and unaffected fami

197 iver transplantation together with prolonged QTc interval.

198 ificantly lower than in those with prolonged QTc intervals (15%) (p < 0.001) but higher than in unaff

199 r ACA or SCD only in patients with prolonged QTc intervals (female age > 13 years, hazard ratio: 1.90

200 stroke in study participants with prolonged QTc(Fram) was almost 3 times the risk in those with norm

201 riteria, in 8526 (52.5%) ECGs with prolonged QTc.

202 dolol, especially in patients with prolonged QTc.

203 by norfluoxetine resulted in more prominent QTc prolongation in mutation carriers than in noncarrier

204 aE2/DeltaE2)) in 129 sv mice results in QRS, QTc widening, bundle block and STc narrowing at 2-4 mont

205 arsenic and QT and heart rate-corrected QT (QTc) durations and to examine effect modification by cal

206 d >/=120 ms (1.75, 1.17-2.62); corrected QT (QTc) interval >/=450 ms in men or >/=460 ms in women (1.

207 stigate whether the heart rate-corrected QT (QTc) interval on the electrocardiogram (ECG) is associat

208 Corrected QT (QTc) interval prolongation (defined as QTc>500 ms or an

209 Female gender, corrected QT (QTc) interval, LQT2 genotype, and frequency of cardiac e

210 QT syndrome (LQTS) with normal corrected QT (QTc) intervals.

211 formation provided by multiple corrected QT (QTc) measurements on serial electrocardiograms (ECGs) in

212 novel and are associated with corrected QT (QTc) prolongation and complex ventricular arrhythmias.

213 s with autoimmune diseases and corrected QT (QTc) prolongation directly target and inhibit the human

214 induced increase in heart rate-corrected QT (QTc) versus drug concentration.

215 s measured, and the heart rate-corrected QT (QTc) was calculated (corrected by using Bazett's rate).

216 the prolongation of heart rate-corrected QT (QTc), PR, and QRS intervals.

217 hisms (SNPs) that modulate the corrected QT (QTc)-interval and the occurrence of cardiac events in 63

218 ontrols; however, resting heart rates and QT/QTc intervals were similar at baseline.

219 ced effect among patients with a lower-range QTc, in whom a patient's individual QTc may provide less

220 tries, categorized as LQTS with normal-range QTc (</= 440 ms [n = 469]), LQTS with prolonged QTc inte

221 SCD in patients with LQTS with normal-range QTc intervals (4%) was significantly lower than in those

222 ors ACA or SCD in patients with normal-range QTc intervals included mutation characteristics (transme

223 etransplant QT-time corrected by heart rate (QTc) and left-ventricular dysfunction was also registere

224 ion of QT interval corrected for heart rate (QTc) with incident stroke.

225 vidual QT interval corrected for heart rate (QTc).

226 of the QT interval corrected for heart rate (QTc).

227 rected by Bazett's formula, for heart rate, (QTc) > or =500 ms at the time of or before the TdP occur

228 the baseline, the mean, and the most recent QTc interval recorded before age 10, were less significa

229 ependent transaminase elevation and relative QTc prolongation were observed with the highest doses of

230 tely 9% to 10% of total variation in resting QTc in EA individuals and approximately 12% to 18% in AA

231 Sixteen probands had normal resting QTc values and only developed QT prolongation and malign

232 Severe QTc prolongation and ERP were more prevalent in people w

233 RP (ORadj 2.4, 95% CI 1.1 to 5.5) and severe QTc prolongation (ORadj 9.9, 95% CI 1.1 to 1317.7).

234 ERP and severe QTc prolongation appear to be more prevalent in people w

235 .05), increased proportion of mild or severe QTc prolongation (13.1% and 5.8% versus 3.4% and 0.0% [N

236 d ECGs for three markers of SCA risk: severe QTc prolongation (male >450 ms, female >470 ms), Brugada

237 INa-L block with lidocaine shortened QTc and APD more at 6.5 hours than at 50 minutes (QTc) o

238 Mexiletine significantly shortened QTc (by 63 +/- 6 ms; p < 0.0001) and reduced the percent

239 Besides shortening QTc interval, mexiletine caused a major reduction of lif

240 h the mutation was associated with a shorter QTc interval (P<0.05) and a reduced occurrence of cardia

241 P<.001) compared with those having a shorter QTc.

242 rol (4.8+/-0.30 and 4.5+/-0.23), and shorter QTc intervals (167+/-2.6 versus 182+/-6.4).

243 Women had significantly shorter QTc compared with men (312 versus 323 ms; P=0.03).

244 0.34 (0.19-0.61; P<0.0002) and with shorter QTc (P<0.0001) in the combined discovery and replication

245 -kDa Ro antigen-immunized guinea pigs showed QTc prolongation on ECG after developing high titers of

246 titres of E-pore peptide Abs and significant QTc prolongation after immunization.

247 airment, sedation, or clinically significant QTc prolongation.

248 e heart weight (3.6+/-0.26), but had similar QTc (179+/-4.3) compared with HF control.

249 n LQTS, the timing and frequency of syncope, QTc prolongation, and sex were predictive of risk for ab

250 during adolescence included recent syncope, QTc interval, and sex.

251 The QTc interval prolongs in 100% of patients with early tra

252 The QTc shortening was significantly less pronounced among p

253 The QTc shortening with propranolol was significantly greate

254 +/-6 versus 115+/-11 beats/min; P=0.54), the QTc interval had prolonged significantly more in patient

255 ear relationship between GRS(NOS1AP) and the QTc-interval (P=4.2x10(-7)).

256 breakthrough LQTS arrhythmic risk beyond the QTc value.

257 and 13 patients with no CAD to correlate the QTc interval respectively.

258 If the QTc interval exceeds 500 ms, consider discontinuing or r

259 COMMENDATION 4 (RISK STRATIFICATION): If the QTc interval is greater than 450 ms but less than 500 ms

260 rocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30

261 Risk factors for prolongation of the QTc interval are chronic hepatitis C-induced cirrhosis,

262 Miscalculation of the QTc, misinterpretation of the normal distribution of QTc

263 pectedly large effects of NOS1AP SNPs on the QTc-interval and a trend for effects on risk of cardiac

264 an analysis for quantitative effects on the QTc-interval, 3 independent SNPs at NOS1AP (rs10494366,

265 with LQT2 and significantly outperformed the QTc (C statistic, 0.82 [0.71-0.93]).

266 Transmural ischemia prolonged the QTc interval (using the Bazett's formula) in 100% of pat

267 Ranolazine reduced the QTc at all heart rates but less so during extreme noctur

268 Concern regarding the QTc interval in human immunodeficiency virus (HIV)-infec

269 he sinus rate or QRS width but shortened the QTc from 509+/-41 to 451+/-26 ms, a mean decrease of 56+

270 When added to the QTc (C statistic 0.68 for QTc alone), discrimination imp

271 .6x10(-7)) were strongly associated with the QTc-interval with marked effects (>12 ms/allele).

272 o treatment discontinuations occurred due to QTc prolongation, and no Torsades de Pointes was reporte

273 0001) in QRS duration but was not related to QTc interval or Sokolow-Lyon index.

274 was precluded by a low therapeutic window to QTc prolongation in cardiovascular models consistent wit

275 Three dose-limiting toxicities (QTc changes) occurred: one at the 700-mg dose (patient d

276 ia (24%), as well as dose-related, transient QTc prolongation (17%).

277 derline (QTc 440 to 469 ms), and unaffected (QTc < 440 ms) subgroups.

278 Other follow-up QTc measures, including the baseline, the mean, and the

279 inical diagnostic score ranging from 0% when QTc was <400 ms to 62% when QTc was >480 ms (p < 0.0001)

280 ing from 0% when QTc was <400 ms to 62% when QTc was >480 ms (p < 0.0001).

281 m patients with autoimmune diseases and with QTc prolongation on the ECG target the human ether-a-go-

282 Height was not associated with QTc interval or the Sokolow-Lyon index.

283 Examining the risk of stroke associated with QTc-prolonging drugs may be warranted.

284 typed based on either their association with QTc duration in healthy populations or on their role in

285 f exercise-induced long QT syndrome but with QTc <480 ms and a subsequent negative long QT syndrome g

286 sed the risk of cardiac events compared with QTc <470 ms (HR, 3.32; P=0.001).

287 tration of L5 was higher and correlated with QTc in patients with CAD compared to controls.

288 ty lipoprotein (LDL), L5, is correlated with QTc prolongation in patients with coronary artery diseas

289 show that L5 was positively correlated with QTc prolongation in patients with ischemic heart disease

290 up and upward, the risk of AF increased with QTc interval duration in a dose-response manner, reachin

291 Patients with QTc of 140 to 340 ms confirmed by a pediatric electrophy

292 i-SSA/Ro Ab-positive sera from patients with QTc prolongation.

293 om baseline; for patients who presented with QTc >500 ms, QTc prolongation was defined solely as incr

294 s in the total cohort and in the subset with QTc >480 ms.

295 val: 1.24 to 1.66, p < 0.001) for those with QTc intervals >/=99th percentile (>/=464 ms).

296 om routine ECG screening and that those with QTc prolongation should receive counseling about drugs t

297 onotherapy, MK-8776 was well tolerated, with QTc prolongation (19%), nausea (16%), fatigue (14%), and

298 de Pointes (TdP), and in an adult woman with QTc >500 ms, atrioventricular block and TdP.

299 ied 128 patients ages 8.0 +/- 5.4 years with QTc of 487 +/- 39 ms and follow-up of 4.4 +/- 3.5 years.

300 f 17 patients (82% male, age 29 +/- 3 years, QTc before treatment 331 +/- 3 ms) received HQ therapy (